Antibiotic resistance isn’t a future problem. It’s here. The pipeline for new antibiotics has basically dried up, and the ones we have are losing ground. But a study published this week in Nature offers something genuinely different: not just a new drug candidate, but a new way to look for them.
Researchers at McMaster University, led by Eric Brown, discovered what they’re calling a “megacluster” – a large block of genes that codes for four molecules working together to shut down a single metabolic pathway in bacteria. That pathway produces biotin, or vitamin B7, which many pathogens need to grow and cause disease.
Here’s why this matters. Most antibiotics are single molecules hitting single targets. One mutation and they’re done. This megacluster produces four separate weapons: three antibiotics (stravidins, acidomycins, dapamycins) that each disable a different enzyme in the biotin pathway, plus a decoy molecule that hijacks the pathway to produce a useless biotin lookalike. Oh, and streptavidin flanks the whole cluster on both sides, sequestering whatever biotin is already there. It’s a siege, not a sniper shot.
The kicker? They found this in Streptomyces – soil bacteria that scientists have been studying for decades. Streptomyces gave us streptomycin in the 1940s. These organisms have been picked over repeatedly. The megacluster was overlooked, probably because labs typically grow bacteria in nutrient-rich media that masks these mechanisms.
Experiments in test tubes and mice confirmed the products kill various bacteria, and they’re more potent in combination. That lines up with how evolution designed them – as a package deal.
Steven Rutherford of Genentech, who wrote an accompanying commentary in Nature, put it plainly: evolution has already identified effective drug combinations. Systems evolved this way may also be harder for bacteria to develop resistance against.
This doesn’t mean new drugs are around the corner. Clinical trials take years and cost billions. But the shift from scanning for individual gene clusters to hunting for megaclusters could reinvigorate natural product drug discovery. Sometimes the best ideas were already invented – we just hadn’t found them yet.
